The Population Council

The Population Council

Founded in 1952 by John D. Rockefeller III, the Population Council emerged from a postwar preoccupation with global demographic growth. Rockefeller acted after convening a conference of demographers and development thinkers in Williamsburg, Virginia. The Council was incorporated as a freestanding nonprofit, distinct from the Rockefeller Foundation, though the Foundation provided early operational funding. Its original mandate combined policy research with direct scientific inquiry — a dual structure that persists across its two main campuses at One Dag Hammarskjold Plaza and the Center for Biomedical Research on York Avenue in New York. Strategy divides between biomedical R&D and social science, often intertwined. The Council's laboratory developed the copper intrauterine device in the 1960s, then Jadelle and Mirena, both long-acting reversible contraceptives later licensed to commercial pharmaceutical partners. Its Annovera contraceptive ring, approved by the FDA in 2018, is manufactured under license by Mayne Pharma. On the social science side, the Council runs longitudinal demographic surveys and girls' education programs, most prominently in sub-Saharan Africa and South Asia. Major funding flows through USAID and the Bill & Melinda Gates Foundation, supporting reproductive health initiatives and community-based interventions that generate the population-level data the Council publishes in its peer-reviewed journal, Population and Development Review. The Council operates with a 501(c)(3) endowment that Altss estimates at $131M. Governance sits with a board chaired by Darcy Stacom, the veteran investment-sales broker who chairs New York City capital markets at CBRE. A Washington, D.C. office houses government-relations and policy staff. World War II and the mid-century rise of development economics shaped the intellectual environment that produced the Council, and its headquarters remains in midtown Manhattan, with satellite research offices embedded in field sites rather than the major financial centers where asset managers cluster. Unlike a fund or foundation that deploys exclusively via grants, the Population Council runs a hybrid structure: it holds intellectual property on FDA-approved medical devices, collects royalties, and reinvests proceeds into new drug-delivery systems and demographic studies. This operating-asset model makes it closer to a translational research institute than to a conventional endowment. Succession from the founder's vision to professionalized governance occurred decades ago, and the relationship with the Gates Foundation now anchors its global health portfolio.